Dofetilide

A Class III antiarrhythmic, FDA-approved to convert atrial fibrillation or flutter to normal rhythm and to maintain normal rhythm afterward.

psilodex.org/m/dofetilide · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~10 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Dofetilide”, v2026.10.05. psilodex.org/m/dofetilide

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Maintenance of normal sinus rhythm after conversion of atrial fibrillation or flutter
Conversion of atrial fibrillation or flutter to normal sinus rhythm

Sources [1]

Other safety

The label requires starting or restarting dofetilide in a facility with creatinine clearance calculation, continuous ECG monitoring and cardiac resuscitation for at least 3 days.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; it changes heart rhythm, and psilocybin briefly raises heart rate and blood pressure.

Detail Dofetilide prolongs the QT interval (a heart-rhythm measure) in proportion to its blood level. It can cause torsades de pointes (a dangerous rhythm). Psilocybin briefly raises heart rate and blood pressure. The two have not been studied together. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~10 h (FDA label, checked 2026-10-04) Longer with reduced kidney function.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

QT-prolonging: Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Cardiovascular disease likely
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

TIKOSYN (dofetilide) capsules (Pfizer) · FDA label (DailyMed) — revised 2026-04 | QT-prolonging: Warnings, Ventricular Arrhythmia "TIKOSYN (dofetilide) can cause serious ventricular arrhythmias, primarily Torsade de Pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation." "QT interval prolongation is directly related to dofetilide plasma concentration." | "The terminal half-life of dofetilide is approximately 10 hours"

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →